NEW YORK, NY and HALIBURTON, ON–(Marketwire – September 23, 2010) – October is National Dental Hygiene Month (NDHM) and it’s also the perfect time to create new dental marketing materials to reach out to your dental patients, says Patient News, a leading dental marketing solutions company.

Effective dentist/patient communication is essential to keeping patients, and a multi-channel patient retention campaign is extremely effective because it’s a means of sharing ideas and knowledge, not selling. NDHM is a great time for dental practitioners to ramp up their communication/marketing efforts and provide much needed and appreciated dental patient education to their patients.

“To build a vibrant and profitable practice it’s important to include a patient-centered marketing approach. Even the healthiest practice can’t help but lose patients over time due to natural attrition, competition, dissatisfaction, and perceived indifference,” said Karen Galley, President of Patient News. “Perceived indifference sends customers away nearly five times more often than dissatisfaction and seven times more often than for competitive reasons. A patient newsletter shows your patients you care.”

A consistent effort to communicate and educate patients, especially when paired with the efforts of the American Dental Hygienists’ Association in October, can reap measurable rewards. The ADHA website includes information to help promote events planned in honor of NDHM. Patient News can improve dentist/patient communications through their extensive resources, including an exceptional article library featuring stories about the importance of dental hygiene — clearly linked to overall health and systemic diseases.

“Although people continue to score smile and appearance of teeth as most important to their personal appearance and place a high value on oral health, more than 80% remain fearful of the dentist. It takes time and quality dental patient education via email and mail to encourage existing and prospective patients to make even a positive change,” said Galley. This type of communication can also assist dentists reduce no shows and cancellations, improving the overall health of the practice and patient community.

For more information on NDHM, visit ADHA.org. For additional information on dental newsletters or dental email newsletter options from Patient News call 800.667.0268 or visit www.Patientnews.com.

Read more: http://www.patientnews.com/pressreleases/educate-patients-during-dental-hygiene-month.html.

About Patient News:

Patient News is North America’s most trusted resource in helping dental practices succeed. The company produces award-winning healthcare and dental marketing products in Canada, the United States, and the United Kingdom.

Click here to see all recent news from this company

TORONTO, ONTARIO–(Marketwire – Sept. 22, 2010) –

Attention: Health and Science Reporters, Assignment and Photo Editors. 

On September 23 2010, media are invited to an in-depth briefing with senior scientists on current stem cell research activity at the McEwen Centre for Regenerative Medicine. McEwen Centre Director, Dr. Gordon Keller will discuss eight “Accelerated Discoveries.” These are research initiatives that include a new project that will push the frontier forward for patients suffering from heart disease, the number one killer in the western world. 

Research at the McEwen Centre also holds important implications for diabetes, lung disease, diseases of the blood as well as neurodegenerative disease.

Please join us to learn more about this exciting research field. The tour will include an opportunity to interview senior scientists and gain new understanding of the latest developments in this cutting edge research. You are also invited to attend a Public Symposium on The Stem Cell Healthcare Revolution which follows the tour at 1:30 p.m. to 3:30 p.m.

Telephone interviews with senior scientists, the McEwens, and patient advocates can be arranged in advance.

LAS VEGAS, NV–(Marketwire – September 22, 2010) –  Medex, Inc. (PINKSHEETS: MDXX), today announced four strategic hires and several facilities expansions intended to foster significant revenue and earnings growth at the Company’s Creative Rehab Technology Services, Inc. and Bee Mobile, Inc. operations.

Kia Davis, 35, has been appointed service coordinator for Creative Rehab and will be based in that company’s newly relocated and expanded facility in Rancho Cucamonga, California. Davis will be responsible for new business development in the greater Los Angeles area as well as contracts management with a growing dealer network there and throughout the Inland Empire.

Additionally, Michael Spradley, 40, has been hired as a seating and mobility specialist. With significant industry contacts and related sales experience, he will be supported by two additional technician hires in San Diego and Escondido, California. These individuals will support sales at Creative Rehab and servicing contracts for Bee Mobile.

In related matters, Medex indicated that facility expansions are in progress at Creative Rehab’s headquarters in Chula Vista, California and that Bee Mobile, in addition to the above referenced Rancho Cucamonga relocation, has acquired an additional 5,000 square foot repair and warehouse facility in Fontana, California to improve efficiency and output of its capacities.

Medex also indicated that Bee Mobile is currently finalizing contractual arrangements with several dealers in the greater Las Vegas area to provide services and repair.

“Growth in demand for products and service necessitate capital investment for both plant infrastructure as well as key personnel. We anticipate that this investment should yield a 30% revenue growth for both companies combined with previously disclosed corresponding cumulative net margin improvement,” said Paul Protzman, President of Medex, Inc. “We are encouraged by current market response to these business lines.”

About Medex, Inc.

Medex, Inc. is a development stage Nevada-based medical support services company, which plans to grow through acquisitions of medical supply companies, medical technology companies, and assisted living and care facilities worldwide. For additional information, see www.medexsynergies.com.

Safe Harbor Statement:

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

OAKBROOK TERRACE, IL–(Marketwire – September 22, 2010) –  Accredited hospitals in the United States are providing higher-quality, evidence-based care for heart attack, pneumonia, surgical care and children’s asthma care, according to Improving America’s Hospitals: The Joint Commission’s Report on Quality and Safety 2010. The report presents scientific evidence of improvement and how it relates to these common medical conditions and procedures.

“It is very encouraging that this year’s report shows high rates of performance on these critical process measures and high levels of consistent excellence among hospitals on many measures,” said Mark R. Chassin, M.D., M.P.P., M.P.H., president, The Joint Commission. “Hospitals devote enormous resources and energy to using these performance measures to drive improvement in their clinical processes. This report demonstrates that these efforts are resulting in consistently improving patient care in America’s hospitals.”

The fifth annual report shows continual improvement over an eight-year period on accountability measures — quality measures that meet four criteria designed to identify measures that produce the greatest positive impact on patient outcomes. For example, the 2009 heart attack care result is 97.7 percent, up from 88.6 percent in 2002. A 97.7 percent score means that hospitals provided an evidence-based heart attack treatment such as aspirin at arrival and beta-blockers at discharge 977 times for every 1,000 opportunities to do so.

The data, drawn from more than 3,000 accredited hospitals, show:

• Significant progress in consistently using evidence-based treatments. In 2002, hospitals achieved 81.8 percent composite performance on 957,000 opportunities to perform care processes related to accountability measures. In 2009, hospitals achieved 95.4 percent composite performance on 12.5 million opportunities — an improvement of 13.6 percentage points.
• Hospital performance on measures of quality relating to inpatient care for childhood asthma has increased dramatically in the two years since being introduced. The 2009 children’s asthma care result is 88.1 percent, up from 70.7 in 2007.
• The 2009 pneumonia care result is 92.9 percent, up from 72.4 percent in 2002 — an improvement of 20.5 percentage points.
• The surgical care result improved to 95.8 percent in 2009 from 77.4 percent in 2004.

Although hospitals achieved 90 percent or better performance on most individual process of care measures, the report contends that more improvement is needed. For example, hospitals finished 2009 with relatively low performance on the following two measures introduced in 2005:

• Providing fibrinolytic therapy within 30 minutes of arrival to heart attack patients — only 55.2 percent of hospitals achieved 90 percent compliance or better.
• Providing antibiotics to intensive care unit pneumonia patients within 24 hours of arrival — only 67.5 percent of hospitals achieved 90 percent compliance or better.

The report, which focuses on accountability measures for the first time, is an effort to clearly demonstrate the impact that performance measures have on improving patient outcomes. Doing so will strengthen the partnerships hospitals have with physicians, nurses, pharmacists and other clinicians who are engaged in the hard work of improving the processes of care. Specific expectations for performance on accountability measures will be included in hospital accreditation standards by 2012.

Quality, safety and patient satisfaction results for specific hospitals can be found at www.qualitycheck.org. For a complete copy of the report Improving America’s Hospitals: The Joint Commission’s Report on Quality and Safety 2010, please visit www.jointcommission.org.

Founded in 1951, The Joint Commission seeks to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. The Joint Commission evaluates and accredits more than 18,000 health care organizations and programs in the United States, including more than 9,700 hospitals and home care organizations, and more than 6,800 other health care organizations that provide long term care, behavioral health care, laboratory and ambulatory care services. In addition, The Joint Commission also provides certification of more than 1,700 disease-specific care programs, primary stroke centers, and health care staffing services. An independent, not-for-profit organization, The Joint Commission is the nation’s oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at www.jointcommission.org.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – September 22, 2010) – ForceLogix Technologies Inc. (TSX-V: FLT) www.ForceLogix.com (the “Company“) announced today that effective September 22, 2010, 340,216 common shares were issued to an Insider (as that term is defined in Exchange Policy 1.1) upon conversion of certain special warrants originally issued to holders at the closing of the Company’s Qualifying Transaction on November 30, 2009. Following issuance of said common shares, the Company has 61,202,615 common shares and 22,552,060 non-exercised special warrants outstanding. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Click here to see all recent news from this company

CLIFTON, NJ–(Marketwire – September 22, 2010) –  Electronic Control Security, Inc. (OTCBB: EKCS) (ECSI), a leading provider of a broad line of electronic security system technologies to the government and private sectors, announced financial results for the fiscal year ended June 30, 2010.

Arthur Barchenko, President and CEO, stated, “We achieved our objective during fiscal 2010 to change the direction of the Company’s marketing effort from that of a prime contractor to the Department of Defense to that of a technology manufacturing resource and support service provider to the large system integrators, dealers/installers and, in certain cases, the end user i.e. nuclear power stations.

“To that end, we achieved net revenues of $4,513,737 for fiscal year 2010 as compared to $3,472,696 for fiscal year 2009, representing an increase of approximately 30%. The increase in net revenues during 2010 as compared to 2009 is attributable equally to increases in both government and private-sector related purchase orders.”

Gross margins for 2010 were 55% as compared to 28% of revenue for the 2009 Period. The increase in gross margin for the fiscal year ended June 30, 2010 compared to the corresponding period in 2009 is primarily attributable to a change in the order mix of equipment sales and support services. We experienced an increase in both higher margin equipment sales as well as design and engineering support service billings which, combined, resulted in the increase in gross margins for the Fiscal 2010 Period.

Selling, general and administrative expenses increased approximately 34% in the 2010 Period to $1,771,923 from $1,318,910 in 2009. The increase is partially attributable to costs relating to the U.N. project in Ethiopia where we incurred significant increases in freight and marketing related expenses. However, the major increase in costs related to management’s decision to recognize and write off certain receivables totaling $629,437 related to two overseas projects in Asia and the Middle East and uncollectible Department of Defense (DoD) program-related expenses. Although we attempted to resolve these issues during the past year, we have not been able to collect these receivables. Based on these results, management has made the decision not to seek the award of DoD prime contracts in the future. 

Mr. Barchenko stated that, “I am also pleased to announce that, on July 30, 2010, the Company paid off the principal balance of $100,000 plus interest completing its short and long-term convertible principal debt obligations.

“During fiscal 2010, the Company submitted proposals on projects for Department of Defense facilities and certain nuclear power stations in the United States and southeast Asia valued at approximately $13,650,000. A number of these DoD and nuclear projects amounting to $2.2 million was awarded and partially shipped during the fourth quarter of fiscal 2010. Most of these proposals are still pending and awaiting approval, funding and award. We anticipate decisions relating to these remaining proposals within the first half of fiscal 2011 with deliveries scheduled through the last six months of fiscal 2011 with deliveries scheduled through the last six months of fiscal 2011 and the first half of fiscal 2012.”

About ECSI

ECSI is a global leader in perimeter security and a quality provider to the Department of Defense, Department of Energy, nuclear power stations, and other large commercial-industrial complexes. The Company designs, manufactures and markets physical electronic security systems for high profile, high threat environments utilizing risk assessment and analysis to determine and address the security needs of its customers. Teaming agreements with major system integrators enable ECSI to support the installation and aftermarket of its products in the U.S. and overseas. ECSI is located at 790 Bloomfield Avenue, Bldg. C-1, Clifton, NJ 07012. Tel: 973-574-8555; Fax: 973-574-8562. For more information on ECSI and its customers, please visit http://www.ecsiinternational.com.

ECSI INTERNATIONAL, INC. SAFE HARBOR STATEMENT: This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to changes in economic conditions generally and in our industry specifically, changes in security technology, legislative or regulatory changes that affect us, the availability of working capital, timing of purchase orders, acceptance of company proposals, changes in costs and the availability of goods and services, the introduction of competing products, changes in our operating strategy or development plans, our ability to attract and retain qualified personnel, changes in our acquisition and capital expenditure plans, sufficiency of cash reserves and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2010 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

NORTHFIELD, IL–(Marketwire – September 22, 2010) – Pharos Innovations today congratulated the Care Continuum Alliance on the launch of its new brand and ongoing work on behalf of organizations and individuals providing healthcare at all stages of well-being.

The Care Continuum Alliance, established in 1999 as the Disease Management Association of America, has completed its transition to a new name and brand that reflect the industry’s evolution toward care across the continuum of health, from wellness and prevention to care management and more complex interventions.

Pharos Innovations, a Care Continuum Alliance member represented on the association’s Board of Directors, provides a unique IVR and Web-based remote patient monitoring/behavior change technology through its Tel-Assurance^® program.

“The continuum of care is as much about keeping the healthy well and minimizing health risks as it is about managing specific conditions,” said Randall E. Williams, MD, CEO of Pharos Innovations. “With its new brand, the Care Continuum Alliance captures the broad variety and value of programs and products we and other CCA members provide.”

Care Continuum Alliance (CCA) members are uniquely positioned to contribute to new models of care and the drive toward wellness, prevention and health information technology spurred by federal reform initiatives. Pharos Innovations and other CCA members offer extensive expertise in health risk assessment, innovative technologies to promote healthful behaviors, care coordination across multiple settings and physician collaborations — skills and activities at the core of the reform law.

Pharos Innovations will exhibit this year at The Forum 10, the annual meeting of the Care Continuum Alliance, Oct. 13 to 15, in Washington, D.C. Visit Pharos at booth #416, at the Hilton Washington hotel, the Forum host site. Learn more about the Forum at TheForum10.org.

About Pharos Innovations
Pharos Innovations is actively involved in transforming the U.S. healthcare delivery system. Pharos offers IVR and Web-based behavior change services and tools that enable payers and providers to cost-effectively and efficiently manage their chronic care population.

Pharos’ main offering, Tel-Assurance, engages, motivates and drives improved self-care. Through Tel-Assurance, participants self-report their health status daily through the phone or Web. This unique approach actively engages individuals with chronic conditions in their healthcare and provides care managers/nurses with real-time information to intervene before symptoms escalate. Tel-Assurance has been proven an effective way to reduce avoidable, all-cause hospital admissions and readmissions and reduce overall healthcare costs among diverse populations.

The Pharos’ solution is strongly validated to show measured clinical improvement and financial impact, is the recipient of the prestigious American Heart Association National Outcomes award and was selected for the first ever National Institutes of Health (NIH) sponsored evaluation of remote monitoring interventions. For more information visit www.pharosinnovations.com or join in on the discussion at our blog, www.thecollaborativeforum.com.

id=”nav_links”>

NEW YORK, NY–(Marketwire – September 22, 2010) –  Send Word Now, the leading provider of emergency notification and on-demand incident management, alerting, and response services, announced today that The Wisconsin Hospital Emergency Preparedness Program will make Send Word Now’s Alert Service available to all hospitals in Wisconsin. The initiative sets a new standard for hospital management and a model for unified communications across a state-wide health care network.

“We were looking for a notification system that could meet our communications needs, and specifically for a system that is easy to use,” affirmed Bob Ritger, Operations Officer for the Emergency Preparedness Program. He added, “Having one system throughout the state will allow us to implement our messaging strategies more easily and consistently throughout Wisconsin hospitals. We look forward to working with Send Word Now on this project over the long-term.”

Tony Schmitz, President and CEO of Send Word Now, said, “We are extremely proud to be able to provide our services to hospitals in Wisconsin. Send Word Now is well suited to support these hospital emergency preparedness initiatives based on its experience and expertise in servicing healthcare providers and hospitals across the country.” 

About Send Word Now

Send Word Now is the leading provider of on-demand alerting and incident management services for both routine and emergency communication. The easy-to-use, web-based emergency notification service is used by government agencies, municipalities, universities, non-profit organizations and businesses, including many Fortune 500 companies, to ensure fast, effective, two-way communication in real-time. Send Word Now’s Alert Tracer® provides a full audit trail of messages sent and received for after-action reporting and follow-up. Designed to reach anyone, anywhere, anytime, with any device over any type of connection, Send Word Now’s mass notification system is capable of transmitting hundreds of thousands of voice and text messages in minutes. The company is headquartered in New York City. Visit Send Word Now on the web at http://www.sendwordnow.com or email us at [email protected]. Follow Send Word Now on Twitter at http://twitter.com/sendwordnow and check out our new blog for industry news and insights at http://www.sendwordnow.com/Company/Blog.

About The Wisconsin Hospital Emergency Preparedness Program

The Wisconsin Hospital Emergency Preparedness Program supports hospital emergency preparedness planning and response to mass casualty incidents or pandemic events. The Wisconsin Hospital Emergency Preparedness Program is funded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (DHHS). 

Click here to see all recent news from this company

ANAHEIM, CA–(Marketwire – September 22, 2010) – Leading wound care experts will present a Poster highlighting results from a multicenter randomized controlled trial (RCT) comparing negative pressure wound therapy (NPWT) between the SNaP® Wound Care System from Spiracur, Inc., of Sunnyvale, Calif., and the Wound V.A.C.® Therapy System from Kinetic Concepts, Inc. of San Antonio, Texas, for the treatment of chronic lower extremity ulcers. The Poster will be presented at the Fall 2010 Symposium on Advanced Wound Care (SAWC) in Anaheim, Calif.

Background:  The SNaP Wound Care System is an ultraportable and disposable NPWT device that was approved by the U.S. Food & Drug Administration (FDA) in August 2009 in a new technology category the FDA defined as “non-powered” NPWT devices. It is currently available for purchase in the U.S. The new system produces the same level of negative pressure as competitive technologies; however, it requires no electric or battery power making treatment completely silent. In addition, the therapy system weighs less than three ounces, enabling patients to wear the device under clothing and resume daily activity during the course of treatment.

About Spiracur, Inc.
Spiracur, Inc. is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation program in 2007. Its first product, the SNaP Wound Care System, grew out of the notion that current negative pressure wound therapies were too cumbersome for patients and clinicians. Spiracur strives to develop products that are truly patient-centric. For more information, please visit http://www.spiracur.com.

SNaP and Spiracur are registered trademarks of Spiracur, Inc.

CENTERVILLE, MA–(Marketwire – September 22, 2010) –  UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) announced today that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.

Dr. Wladyslaw Jan Kowalski, PE, Phd, a world leading expert on the bacteria killing efficacy of ultraviolet light, recently commented on the UV-400: “Ultraviolet germicidal irradiation (UVGI) destroys bacteria by damaging the nucleic acids and thereby preventing reproduction. Multidrug-resistant microbes (superbugs) may have resistance to antibiotics but they remain as susceptible to ultraviolet radiation as any normal bacteria variant. The number of multidrug resistant microbes has been increasing, apparently due to overuse of antibiotics and other factors, and is expected to pose a serious challenge to health care facilities in the future as treatment options diminish.”

Dr. Kowalski further added, “The ViraTech UV-400 model air cleaner has a demonstrated ability to disinfect air and inactivate a wide range of bacterial pathogens including Staphylococcus aureus (MRSA), Pseudomonas, and Klebsiella as has been conclusively demonstrated in independent laboratory tests. The UV-400 produces a germicidal UV exposure dose of 41 J/m², as independently verified by biodosimetric testing, which is sufficient to reduce pathogenic bacterial populations by at least 99%. This disinfection rate will apply regardless of the multidrug resistance of bacteria such as those that may contain the NDM-1 enzyme (the superbug gene). The ViraTech UV-400 unit provides a viable option for health care facilities struggling to cope with the growing problem of multidrug resistant organisms and this technology can serve as an adjunct to existing infection management procedures and disinfection protocols wherever the potential exists for microorganisms to spread by the airborne route.”

“Our Company receives reports from around the world on an almost daily basis about the growing problems connected with the spread of these increasingly drug resistant bacterial strains,” said Jack Lennon, President of UV Flu Technologies. “Antibiotics have become so pervasive in today’s medical therapies, that not only are they becoming less effective, but their overuse is increasingly being considered as part of the problem. Drug-resistant superbugs have now been found in 20 states, as well as worldwide, and when they hit the critically ill, they can be fatal 30-60% of the time. In one recent incident at an infant ward at the University College Hospital in London, 15 babies in the unit were found to be carrying several types of bacteria, including 13 who had bacterial superbugs resistant to treatment. Of four babies seriously infected, one survived.”

“So that the public can participate in actions to help reduce the spread of these strains, the Company has committed to advertising, including television and other media in order to educate consumers and to offer help where needed,” said Mr. Lennon. “We are looking to develop a plan to offer our UV-400 indoor air quality units either free or at significantly discounted costs to those schools and hospitals that suffer from serious outbreaks. We hope to partner with institutions which are genuinely interested in working with us in order to develop an action plan for their facilities. For those with respiratory problems or weakened immune systems, hospital or institution acquired bacterial infections can prove deadly. We believe our product delivers an immediate, effective and proven ability to kill at least 99% of airborne bacteria thereby reducing the risk of infection.”

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available without a prescription. 

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Click here to see all recent news from this company

AMSTERDAM, THE NETHERLANDS–(Marketwire – September 22, 2010) –  Information Builders, the independent leader in operational business intelligence (BI) systems, today announced that The Dutch Cancer Institute — Antoni van Leeuwenhoek Hospital (NKI-AVL) has implemented the WebFOCUS BI platform. Using Information Builders’ technology, the NKI-AVL is able to optimize internal processes and to reduce operational costs.

The NKI-AVL consists of a center for scientific cancer research, the Dutch Cancer Institute, and an oncologic hospital, the Antoni van Leeuwenhoek Hospital. The NKI-AVL collaborates with national and foreign hospitals and laboratories and fulfills a leading role with regard to new developments in the fight against cancer.

This year, the NKI-AVL started an expansion process with the ultimate goal of growing up to 45 percent within the next ten years. To facilitate its growth, the institute needed to increase efficient operational processes and decrease operational costs. To measure the efficiency targets in the expansion plan and to gain better insight into costs, the NKI-AVL decided to select a suitable reporting and analysis environment. 

After a comprehensive and detailed tendering process, based on a pilot project, the NKI-AVL selected Information Builders’ WebFOCUS. The BI platform will first be deployed to gain insights in the production and financial information from the SAP and ChipSoft systems. In the second phase, all the research data from the NKI-AVL will be extracted as well.

“WebFOCUS is a multilateral platform. Many other BI solutions mainly focus on finance, while with this platform we are perfectly able to extract and share our healthcare and research information as well,” says Michel Glintmeijer, Head of Information and Financial Services at the NKI-AVL. “We used to connect SAP and ChipSoft through Excel, now we can rely on one reporting tool for all systems. With this solution, we gain much more insight in a much shorter time frame. Ultimately, we will set up a data warehouse and will start with forecasting based on scenario analytics.”

“We are very pleased that the NKI-AVL has selected Information Builders as a strategic partner to implement process optimization and aid with organizational growth,” says Dave Kemme, sales manager, Benelux, at Information Builders. “WebFOCUS offers the NKI-AVL the opportunity to present all relevant information company wide to the management and employees. Furthermore, the organization can start working with scenario planning based on analysis. An extra advantage is that the NKI-AVL will be able to measure governmental performance indicators that are automatically included in WebFOCUS.”

About NKI-AVL
The Dutch Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL) accommodates approximately 550 scientists and scientific support personnel, 53 medical specialists, 180 beds, an outpatient clinic that receives 24,000 new patients each year, 5 operating theaters, and 9 irradiation units. It is the only dedicated cancer center in The Netherlands and maintains an important role as a national and international center of scientific and clinical expertise, development, and training. The three major areas of research are fundamental, clinical, and translational cancer research.

From its first inception, the NKI-AVL is convinced close collaboration between scientists and clinicians is essential to fighting cancer. Having a laboratory and hospital under one roof in a single independent organization with an open and collaborative atmosphere has led to many important discoveries and improved therapies.

About Information Builders
Information Builders’ award-winning combination of business intelligence (BI) and enterprise integration software has been providing innovative solutions to more than 12,000 customers for the past 30 years. WebFOCUS is the world’s most widely utilized business intelligence platform. It provides the security, scalability, and flexibility needed at every level of global extended enterprises. Its simplicity helps create executive, analytical, and operational applications that reach dozens to millions of users. Information Builders’ iWay Software suite provides state of the art, multi-purpose, pre-built integration components that address all SOA, application, data and information management requirements. Its integration adapters have been adopted by the leading software platform providers. Information Builders also offers solutions in the performance management, business activity monitoring, and enterprise search markets. The company’s comprehensive enterprise product offerings give Information Builders’ customers the ability to grow and innovate according to their needs.

Information Builders’ customers include most of the Fortune 100 and U.S. federal government agencies. Headquartered in New York City with 90 offices worldwide, the company employs 1,450 people and has more than 350 business partners. More information is available at informationbuilders.com.

Click here to see all recent news from this company

BOCA RATON, FL–(Marketwire – September 22, 2010) –  Vicor Technologies, Inc. (OTCBB: VCRT), today announced that CEO David Fater’s interview by The Wall Street Transcript for its September 20, 2010 Medical Devices Report is now available for download at the company’s website: www.vicortech.com. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

“We are gratified to have been given the opportunity to discuss Vicor’s product commercialization status in The Wall Street Transcript‘s Medical Devices Report. This is an exciting time for Vicor and we’re eager to share our progress with those following the evolving medical device industry,” stated Mr. Fater.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i^® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Institute for Surgical Research of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-16

Click here to see all recent news from this company

ST. LOUIS, MO–(Marketwire – September 22, 2010) –  Life Uniform, the leader for today’s healthcare fashion trends, will be launching a new and exclusive collection of Laura Ashley medical apparel on September 30^th, 2010 nationwide. Building on a tradition of providing fashion-forward styles, innovative products, the most popular brands, and exclusive styles for 45 years, Life Uniform will introduce their latest fashion in medical scrubs under the Laura Ashley name. Laura Ashley has granted exclusive licensing rights to Life Uniform to design, manufacture, and sell medical scrub tops and pants through their retail outlets and online.

“The Life Uniform and Laura Ashley collaboration is a great opportunity to offer consumers fashionable, affordable, and premium quality medical apparel that encompasses the essence of two great brands,” says Life Uniform’s President and CEO Jim Rudd. “We are excited to bring another fashion choice to our customers who look for distinctive designs that reflect their own individual style.”

“The field of healthcare is dominated by women who are looking for styles and colors that reflect their individual personalities,” says Laura Ashley Vice President of Licensing Penne Cairoli. “We believe the classic yet contemporary style of Laura Ashley will resonate exceptionally well with so many of the dedicated professionals throughout this field.”

The new Laura Ashley medical scrubs can be found in all Life stores and online beginning September 30^th, 2010 with a special in-store celebration on that day to include refreshments and drawings.

About Life Uniform
Life Uniform, headquartered in St. Louis, MO, has been providing fashionable medical uniforms and accessories since 1965. With nearly 200 stores nationwide, on premise hospital stores and a sophisticated online store, Life Uniform is a one-stop shopping destination for all healthcare apparel, medical uniforms, scrubs, nurses shoes, lab coats, hosiery and healthcare accessory needs. Life Uniform represents top brands including Cherokee, Dickies, Barco, Landau, Koi, Dansko and many others, including exclusive merchandise that only Life carries including the new Laura Ashley line of medical scrubs. They also sell their own product line, Life Uniform, which reflects the Life philosophy of STYLE and VALUE.

For more information, visit Life Uniform or call Deb Weis, VP of Marketing at 314-824-2906.

About Laura Ashley
Laura Ashley, Inc., headquartered in Fort Mill, S.C., is the master franchising and licensing holder of the Laura Ashley brand in North and South America. The company strives to be the ultimate destination brand for home products, women’s wear and children’s wear. Licensed categories include bed linen, mattresses, women and children’s clothing and accessories, and much more. For additional information visit www.lauraashley-usa.com.

MIAMI, FL–(Marketwire – September 22, 2010) –  Simulated Environment Concepts (PINKSHEETS: SMEV) a/k/a SE Concepts, manufacturer and developer of medical, aesthetic and wellness equipment, announced that the Dermscan Group is close to wrapping up its clinical trial research on the SpaCapsule and the equipment’s medical benefits.

Dr. Ella Frenkel, Chairman and CEO of Simulated Environment Concepts, Inc. said, “SE Concepts tirelessly strives to develop products which return dividends to our customers by way of overall improved health. The Spa Capsule does just that. In allowing users to not only feel de-stressed and refreshed after each therapeutic session, but internally renewed, we’re able to deliver a product to the medical and wellness community that simply pays for itself.”

The international cosmetic and clinical research company, Dermscan, began its study during late spring of this year with an expected completion time of early to late October 2010. Due to the great emphasis on weight loss, cellulite reduction and therapeutic use in Europe, Dermscan took to task proving just a few of the medical benefits derived from using the SpaCapsule. Results of the study are anticipated to lend to the increasing international appeal of the SpaCapsule — possibly doubling its current global distribution commitment.

Dr. Ilya Spivak, Marketing Director and co-inventor of the SpaCapsule stated, “From this study we deduce that the Spa Capsule will continue to grow as a medical apparatus that is a ‘must have’ by the physical therapy, rehabilitation and pain management community. Being a doctor myself, many times I’ve witnessed the reversing affects that the Spa Capsule has on ailments. Frankly, it is quite amazing.”

Sources close to SE Concepts say the company is receiving much international fan fare from the incredible results achieved by those continuously using the Spa Capsule. It is strongly believed a positive reporting from Dermscan will continue to fuel the current growth of the product within the medical and wellness industries worldwide.

About Simulated Environment Concepts, Inc.

Simulated Environment Concepts, Inc. is the developer of a variety of products for wellness, relaxation, weight loss, and rehabilitation. Our aqua massage and hydromassage products are used by Doctors, Gyms, Spas, retail locations, offices, and many other venues. Incorporating oxygen, aromatherapy, massage, and even music or video from an iPod or an iPhone, our products deliver consistent results and excellent earning potential for businesses. For more information on Simulated Environment Concepts and its flagship product, SpaCapsule®, PTjetCapsule™, and Celude Laboratories™ products you can visit the company’s product website at www.spacapsule.com, the corporate website at www.seccorporation.com, or request more information via email at [email protected], or call at (888) 757-0797 or (305) 651-9200.

Safe Harbor

Statements in this news release that are not historical facts, including statements about plans and expectations regarding products and opportunities, demand and acceptance of new or existing products, capital resources and future financial results are forward-looking. Forward-looking statements involve risks and uncertainties which may cause the Company’s actual results in future periods to differ materially from those expressed. These uncertainties and risks include changing consumer preferences, lack of success of new products, loss of the Company’s customers, competition and other factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

SpaCapsule is registered trademark of Simulated Environment Concepts, Inc.

Click here to see all recent news from this company